EX-99.2 3 a2021q2exhibit992final.htm EX-99.2 Document

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SECOND QUARTER
Percent Change
20212020TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $11,919  9,539  24.9 % 24.9 — 
Europe 5,668  4,063 39.5  28.6  10.9
Western Hemisphere excluding U.S. 1,367  1,133  20.6  12.7  7.9
Asia-Pacific, Africa 4,358  3,601  21.0  14.8  6.2
International 11,393  8,797  29.5  20.9  8.6
      
Worldwide $23,312  18,336  27.1 % 23.0  4.1
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.







Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SIX MONTHS
Percent Change
20212020TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $23,030  20,238  13.8 % 13.8 — 
Europe 11,082  8,890  24.7  15.6  9.1
Western Hemisphere excluding U.S. 2,791  2,635  5.9  5.4  0.5
Asia-Pacific, Africa 8,730  7,264  20.2  14.2  6.0
International 22,603  18,789  20.3  13.7  6.6
      
Worldwide $45,633  39,027  16.9 % 13.7  3.2
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SECOND QUARTER
 Percent Change
20212020TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$1,751 1,557 12.4 %12.4 — 
    International1,984 1,739 14.1 6.3 7.8 
3,735    3,296 13.3 9.2 4.1 
Pharmaceutical
    U.S.6,869 6,120 12.2 12.2— 
    International5,730 4,632 23.7 15.48.3 
12,599    10,752 17.2 13.63.6 
Medical Devices
    U.S.3,299    1,862 77.2 77.2 — 
    International3,679 2,426 51.6 41.9 9.7 
 6,978    4,288 62.7 57.2 5.5 
U.S.11,919 9,539 24.9 24.9 — 
International11,393 8,797 29.5 20.9 8.6 
Worldwide$23,312 18,336 27.1 %23.0 4.1 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SIX MONTHS
 Percent Change
20212020TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$3,362 3,297 2.0 %2.0 — 
    International3,916 3,624 8.1 3.3 4.8 
7,278    6,921 5.2 2.7 2.5 
Pharmaceutical
    U.S.13,315 12,181 9.3 9.3— 
    International11,483 9,705 18.3 11.46.9 
24,798    21,886 13.3 10.33.0 
Medical Devices
    U.S.6,353    4,760 33.5 33.5 — 
    International7,204 5,460 31.9 24.5 7.4 
 13,557    10,220 32.7 28.7 4.0 
U.S.23,030 20,238 13.8 13.8 — 
International22,603 18,789 20.3 13.7 6.6 
Worldwide$45,633 39,027 16.9 %13.7 3.2 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
SECOND QUARTER
20212020Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$23,312 100.0$18,336 100.027.1 
Cost of products sold7,587 32.56,579 35.915.3
Gross Profit15,725 67.511,757 64.133.8 
Selling, marketing and administrative expenses6,073 26.14,993 27.221.6 
Research and development expense3,394 14.62,707 14.825.4 
In-process research and development00.06 0.0
Interest (income) expense, net28 0.1 26 0.2 
Other (income) expense, net(488)(2.1)24 0.1  
Restructuring56 0.261 0.3 
Earnings before provision for taxes on income6,662 28.63,940 21.569.1 
Provision for taxes on income384 1.7314 1.7 22.3 
Net earnings$6,278 26.9$3,626 19.873.1 
Net earnings per share (Diluted)$2.35 $1.36 72.8 
Average shares outstanding (Diluted)2,671.6 2,665.5 
Effective tax rate5.8 %8.0 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$7,776 33.4$5,337 29.145.7 
Net earnings$6,625 28.4$4,446 24.249.0 
Net earnings per share (Diluted)$2.48 $1.67 48.5 
Effective tax rate14.8 %16.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.





Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
SIX MONTHS
20212020Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$45,633 100.0$39,027 100.016.9 
Cost of products sold14,650 32.113,641 35.07.4
Gross Profit30,983 67.925,386 65.022.0 
Selling, marketing and administrative expenses11,505 25.210,196 26.112.8 
Research and development expense6,572 14.45,287 13.524.3 
In-process research and development00.0 6 0.0 
Interest (income) expense, net76 0.2 (16)0.0  
Other (income) expense, net(1,370)(3.0)(655)(1.7) 
Restructuring109 0.2119 0.3 
Earnings before provision for taxes on income14,091 30.910,449 26.834.9 
Provision for taxes on income1,616 3.61,027 2.7 57.4 
Net earnings$12,475 27.3$9,422 24.132.4 
Net earnings per share (Diluted)$4.67 $3.53 32.3 
Average shares outstanding (Diluted)2,674.0 2,671.0 
Effective tax rate11.5 %9.8 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$16,067 35.2$12,581 32.227.7 
Net earnings$13,549 29.7$10,600 27.227.8 
Net earnings per share (Diluted)$5.07 $3.97 27.7 
Effective tax rate15.7 %15.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.









Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Second Quarter
(Dollars in Millions Except Per Share Data)20212020
Net Earnings, after tax- as reported$6,278$3,626
Pre-tax Adjustments
Intangible Asset Amortization expense1,202 1,127
Litigation related(23)613
IPR&D -  6
Restructuring related108 115
Acquisition, integration and divestiture related 14 29
Unrealized (gains)/losses on securities (243)(533)
Medical Device Regulation5637
Other-3
Tax Adjustments
Tax impact on special item adjustments 1
(135)(253)
Tax legislation and other tax related(632) (324)
Adjusted Net Earnings, after tax$6,625$4,446
Average shares outstanding (Diluted)2,671.6 2,665.5
Adjusted net earnings per share (Diluted)$2.48$1.67
Operational adjusted net earnings per share (Diluted)$2.42 
Notes:
1
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.





Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Six Months Ended
(Dollars in Millions Except Per Share Data)20212020
Net Earnings, after tax- as reported$12,475$9,422
Pre-tax Adjustments
Intangible Asset Amortization expense2,417 2,245
Litigation related(23)733
IPR&D - 6
Restructuring related212 233
Acquisition, integration and divestiture related ¹(524)(933)
Unrealized (gains)/losses on securities (208)(206)
Medical Device Regulation102  51
Other -  3
Tax Adjustments
Tax impact on special item adjustments 2
(248)(520)
Tax legislation and other tax related(654) (434)
Adjusted Net Earnings, after tax$13,549$10,600
Average shares outstanding (Diluted)2,674.0 2,671.0
Adjusted net earnings per share (Diluted)$5.07$3.97
Operational adjusted net earnings per share (Diluted)$4.91 
Notes:
1
Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. The six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.








Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 13.3 %17.2 %62.7 %27.1 %
 U.S. 12.4 %12.2 %77.2 %24.9 %
 International 14.1 %23.7 %51.6 %29.5 %
 WW Currency 4.13.65.54.1
 U.S.
 International 7.88.39.78.6
 WW Operational 9.2 %13.6 %57.2 %23.0 %
 U.S. 12.4 %12.2 %77.2 %24.9 %
 International 6.3 %15.4 %41.9 %20.9 %
General Surgery
Advanced Sterilization Products1.20.2
 U.S. 0.00.0
 International 1.90.4
All Other Acquisitions and Divestitures0.80.60.30.6
 U.S. 0.6(0.1)0.70.1
 International 1.11.50.01.0
WW Adjusted Operational10.0 %14.1 %58.7 %23.8 %
 U.S. 13.0 %12.1 %77.9 %25.1 %
 International 7.4 %16.8 %43.8 %22.4 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 5.2 %13.3 %32.7 %16.9 %
 U.S. 2.0 %9.3 %33.5 %13.8 %
 International 8.1 %18.3 %31.9 %20.3 %
 WW Currency 2.53.04.03.2
 U.S.
 International 4.86.97.46.6
 WW Operational 2.7 %10.3 %28.7 %13.7 %
 U.S. 2.0 %9.3 %33.5 %13.8 %
 International 3.3 %11.4 %24.5 %13.7 %
General Surgery
Advanced Sterilization Products0.80.2
 U.S. 0.00.0
 International 1.50.4
All Other Acquisitions and Divestitures0.60.50.20.4
 U.S. 0.5(0.1)0.50.1
 International 0.71.20.00.8
WW Adjusted Operational3.3 %10.7 %29.7 %14.4 %
 U.S. 2.5 %9.2 %33.9 %13.9 %
 International 4.0 %12.6 %26.0 %14.8 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20212020Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US$6756277.7 %7.7 %— %
Intl63352221.2 10.4 10.8 
WW1,3071,14913.8 8.9 4.9 
SKIN HEALTH / BEAUTY
US65953623.0 23.0 — 
Intl5114718.4 1.4 7.0 
WW1,170 1,00716.2 12.9 3.3 
ORAL CARE
US165170(3.1)(3.1)— 
Intl26022714.6 6.7 7.9 
WW426 397 7.0 2.5 4.5 
BABY CARE
US97960.8 0.8 — 
Intl29026011.5 6.6 4.9 
WW387 356 8.6 5.0 3.6 
WOMEN'S HEALTH
US33(3.1)(3.1)— 
Intl22719914.2 9.2 5.0 
WW23020213.9 9.0 4.9 
WOUND CARE / OTHER
US15312620.9 20.9 — 
Intl64597.3 (2.8)10.1 
WW21618516.6 13.4 3.2 
TOTAL CONSUMER HEALTH
US1,751 1,557 12.4 12.4  
Intl1,984 1,739 14.1 6.3 7.8 
WW$3,735 3,296 13.3 %9.2 %4.1 %
See footnotes at end of schedule






Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$2,7482,36216.4 %16.4 %— %
Intl1,4831,16127.7 18.2 9.5 
WW4,2313,52320.1 17.0 3.1 
     REMICADE
     US540593(9.1)(9.1)— 
     US Exports (4)
93133(30.0)(30.0)— 
     Intl25520822.4 11.1 11.3 
     WW888935(5.1)(7.6)2.5 
     SIMPONI / SIMPONI ARIA
     US29025612.8 12.8 — 
     Intl2942891.7 (3.8)5.5 
     WW5845466.9 4.0 2.9 
     STELARA
     US1,4961,13831.4 31.4 — 
     Intl77855839.2 28.6 10.6 
     WW2,2741,69734.0 30.5 3.5 
     TREMFYA
     US325 241 35.0 35.0 — 
     Intl155 101 52.3 41.1 11.2 
     WW479 342 40.2 36.8 3.4 
     OTHER IMMUNOLOGY
     US5  **— 
     Intl1 3 (61.3)(67.9)6.6 
     WW7 3 ***
INFECTIOUS DISEASES
US4444166.8 6.8 — 
Intl58546326.3 18.2 8.1 
WW1,02887817.1 12.8 4.3 
     COVID-19 VACCINE
     US51**— 
     Intl113**— 
     WW164**— 
     EDURANT / rilpivirine
     US9 10 (9.3)(9.3)— 
     Intl253 246 2.8 (4.0)6.8 
     WW262 256 2.3 (4.2)6.5 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US368379(3.2)(3.2)— 
     Intl1371305.5 (5.9)11.4 
     WW505510(1.0)(3.9)2.9 
     OTHER INFECTIOUS DISEASES
     US1625(36.2)(36.2)— 
     Intl8187(6.2)(13.4)7.2 
     WW98113(13.0)(18.5)5.5 
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$8427788.0%8.0%—%
Intl96780919.613.16.5
WW1,8081,58713.910.63.3
     CONCERTA / methylphenidate
     US3555(36.0)(36.0)
     Intl1279433.725.68.1
     WW1611498.13.05.1
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US64557611.911.9
     Intl380303 25.115.99.2
     WW1,02487916.413.33.1
     RISPERDAL CONSTA
     US7274(3.0)(3.0)
     Intl84796.40.26.2
     WW1551531.9(1.3)3.2
     OTHER NEUROSCIENCE
     US917520.920.9
     Intl37733113.810.03.8
     WW46840615.112.03.1
ONCOLOGY
US1,4621,18123.7 23.7 
Intl2,073 1,609 28.8 19.8 9.0
WW3,5352,79126.7 21.5 5.2
     DARZALEX
     US770 492 56.7 56.7 
     Intl663 409 62.1 50.3 11.8
     WW1,433 901 59.2 53.8 5.4
     ERLEADA
     US193 136 41.5 41.5 — 
     Intl109 33 ***
     WW302 170 77.6 73.7 3.9 
     IMBRUVICA
     US454 447 1.7 1.7 
     Intl662 502 31.9 22.1 9.8
     WW1,116 949 17.7 12.5 5.2
     ZYTIGA / abiraterone acetate
     US2187 (75.3)(75.3)
     Intl54248012.8 5.4 7.4
     WW563568(0.8)(7.1)6.3
     OTHER ONCOLOGY
     US23 20 18.8 18.8 
     Intl97185(47.2)(49.6)2.4
     WW120204(40.9)(43.0)2.1
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$595 545 9.0 %9.0 %— %
Intl275 243 13.5 7.9 5.6 
WW870 789 10.4 8.7 1.7 
     OPSUMIT
     US290 256 13.6 13.6 — 
     Intl172 150 14.9 9.0 5.9 
     WW463 406 14.1 11.9 2.2 
     UPTRAVI
     US268 254 6.0 6.0 — 
     Intl45 28 54.9 42.9 12.0 
     WW313 282 11.0 9.8 1.2 
     OTHER PULMONARY HYPERTENSION
     US36 37 (2.4)(2.4)— 
     Intl59 64 (8.2)(10.3)2.1 
     WW95 101 (6.1)(7.5)1.4 
CARDIOVASCULAR / METABOLISM / OTHER
US780837(6.9)(6.9)— 
Intl346347(0.3)(8.4)8.1 
WW1,1261,184(5.0)(7.3)2.3 
     XARELTO
     US569 559 1.8 1.8 — 
     Intl  — — — 
     WW569 559 1.8 1.8 — 
     INVOKANA / INVOKAMET
     US96 132 (27.0)(27.0)— 
     Intl64 47 33.8 22.1 11.7 
     WW160 179 (10.9)(14.0)3.1 
     PROCRIT / EPREX
     US59 70 (16.3)(16.3)— 
     Intl69 66 3.7 (4.5)8.2 
     WW127 136 (6.6)(10.6)4.0 
     OTHER
     US57 78 (26.7)(26.7)— 
     Intl214 234 (8.4)(15.7)7.3 
     WW271 312 (13.0)(18.4)5.4 
TOTAL PHARMACEUTICAL
US6,8696,12012.2 12.2  
Intl5,7304,63223.7 15.4 8.3 
WW$12,59910,75217.2 %13.6 %3.6 %
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US$475 255 86.5 %86.5 %— %
Intl572 33570.5 59.8 10.7 
WW1,046 59077.4 71.3 6.1 
ORTHOPAEDICS
US1,323 869 52.3 52.3 — 
Intl904 583 55.1 43.2 11.9 
WW2,227 1,451 53.4 48.6 4.8 
     HIPS
     US234 137 70.5 70.5 — 
     Intl159 88 78.6 64.3 14.3 
     WW392 226 73.7 68.1 5.6 
     KNEES
     US210 108 94.3 94.3 — 
     Intl140 66 *95.1 16.8 
     WW350 174 *94.6 6.4 
     TRAUMA
     US447 354 26.0 26.0 — 
     Intl263 198 32.7 22.7 10.0 
     WW710 553 28.4 24.8 3.6 
     SPINE, SPORTS & OTHER
     US433 270 60.6 60.6 — 
     Intl343 230 49.0 37.9 11.1 
     WW776 499 55.3 50.2 5.1 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (Continued)
SURGERY
US$1,035 490 **— %
Intl1,487 1,060 40.2 30.6 9.6 
WW2,522 1,551 62.6 56.0 6.6 
     ADVANCED
US459 277 65.4 65.4  
Intl708 498 42.2 32.5 9.7 
WW1,168 775 50.5 44.3 6.2 
     GENERAL
US576 213 ** 
Intl779 562 38.5 28.9 9.6 
WW1,354 775 74.7 67.8 6.9 
VISION
US467 248 88.3 88.3  
Intl716 447 60.0 53.7 6.3 
WW1,183 695 70.1 66.0 4.1 
     CONTACT LENSES / OTHER
US352 203 73.3 73.3  
Intl517 352 47.0 41.9 5.1 
WW868 554 56.7 53.4 3.3 
     SURGICAL
US115 45 **— 
Intl199 96 *97.1 10.6 
WW314 141 ***
TOTAL MEDICAL DEVICES
US3,299 1,862 77.2 77.2  
Intl3,679 2,426 51.6 41.9 9.7 
WW$6,978 4,288 62.7 %57.2 %5.5 %
See footnotes at end of schedule








Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20212020Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US$1,2741,316(3.2)%(3.2)%— %
Intl1,2081,1812.3 (4.7)7.0 
WW2,4822,497(0.6)(3.9)3.3 
SKIN HEALTH / BEAUTY
US1,2931,1958.2 8.2 — 
Intl1,04092912.0 6.8 5.2 
WW2,333 2,1249.8 7.6 2.2 
ORAL CARE
US328346(5.2)(5.2)— 
Intl51444615.3 10.2 5.1 
WW843 792 6.3 3.5 2.8 
BABY CARE
US1931882.4 2.4 — 
Intl58352910.2 9.0 1.2 
WW776 717 8.1 7.3 0.8 
WOMEN'S HEALTH
US67(16.0)(16.0)— 
Intl4464274.5 3.1 1.4 
WW4524344.2 2.8 1.4 
WOUND CARE / OTHER
US2682459.3 9.3 — 
Intl12511112.1 5.2 6.9 
WW39335610.2 8.0 2.2 
TOTAL CONSUMER HEALTH
US3,362 3,297 2.0 2.0  
Intl3,916 3,624 8.1 3.3 4.8 
WW$7,278 6,921 5.2 %2.7 %2.5 %
See footnotes at end of schedule






Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$5,1614,7728.2 %8.2 %— %
Intl2,9842,38924.9 17.0 7.9 
WW8,1457,16113.7 11.1 2.6 
     REMICADE
     US1,0291,218(15.6)(15.6)— 
     US Exports (4)
150243(38.2)(38.2)— 
     Intl4874644.9 (1.7)6.6 
     WW1,6651,925(13.5)(15.1)1.6 
     SIMPONI / SIMPONI ARIA
     US5455283.2 3.2 — 
     Intl6015479.8 4.5 5.3 
     WW1,1461,0756.6 3.8 2.8 
     STELARA
     US2,8272,35520.0 20.0 — 
     Intl1,5951,16137.3 28.1 9.2 
     WW4,4223,51625.8 22.7 3.1 
     TREMFYA
     US599 428 40.0 40.0 — 
     Intl298 210 41.8 31.8 10.0 
     WW897 638 40.6 37.3 3.3 
     OTHER IMMUNOLOGY
     US12  **— 
     Intl3 6 (51.2)(53.9)2.7 
     WW15 6 ***
INFECTIOUS DISEASES
US95685212.2 12.2 — 
Intl1,07994614.1 7.8 6.3 
WW2,0351,79813.2 9.9 3.3 
     COVID-19 VACCINE
     US151**— 
     Intl113**— 
     WW264**— 
     EDURANT / rilpivirine
     US19 22 (10.9)(10.9)— 
     Intl486 458 6.0 (1.7)7.7 
     WW505 480 5.2 (2.1)7.3 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US748775(3.5)(3.5)— 
     Intl303314(3.5)(8.5)5.0 
     WW1,0511,089(3.5)(5.0)1.5 
     OTHER INFECTIOUS DISEASES
     US3754(31.3)(31.3)— 
     Intl1771741.8 (3.0)4.8 
     WW215229(6.1)(9.7)3.6 
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$1,6131,5265.6 %5.6 %— %
Intl1,9161,71911.5 6.3 5.2
WW3,5293,2458.7 6.0 2.7
     CONCERTA / methylphenidate
     US82107(23.1)(23.1)
     Intl25021217.511.16.4
     WW3323203.9(0.3)4.2
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US1,2341,12010.2 10.2 
     Intl756642 17.7 9.9 7.8
     WW1,9891,76212.9 10.1 2.8
     RISPERDAL CONSTA
     US139150(7.5)(7.5)
     Intl1731730.4(4.6)5.0
     WW312323(3.3)(6.0)2.7
     OTHER NEUROSCIENCE
     US1581505.65.6
     Intl7386916.74.32.4
     WW8968416.54.52.0
ONCOLOGY
US2,8392,35620.520.5
Intl4,266 3,448 23.716.27.5
WW7,1055,80422.417.94.5
     DARZALEX
     US1,461 955 53.153.1
     Intl1,337 883 51.442.39.1
     WW2,798 1,838 52.247.94.3
     ERLEADA
     US364 255 42.742.7
     Intl199 57 ***
     WW563 313 80.076.43.6
     IMBRUVICA
     US898 879 2.22.2
     Intl1,342 1,101 21.914.27.7
     WW2,241 1,980 13.28.94.3
     ZYTIGA / abiraterone acetate
     US71 226 (68.5)(68.5)
     Intl1,1301,0329.52.57.0
     WW1,2011,258(4.5)(10.3)5.8
     OTHER ONCOLOGY
     US44 42 6.36.3
     Intl258375(31.0)(34.3)3.3
     WW302416(27.3)(30.2)2.9
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$1,168 1,031 13.2 %13.2 %— %
Intl563 503 12.1 6.7 5.4 
WW1,731 1,534 12.9 11.1 1.8 
     OPSUMIT
     US562 485 15.9 15.9 — 
     Intl351 310 13.1 7.6 5.5 
     WW913 795 14.8 12.7 2.1 
     UPTRAVI
     US527 466 13.3 13.3 — 
     Intl91 66 36.8 27.4 9.4 
     WW618 532 16.2 15.0 1.2 
     OTHER PULMONARY HYPERTENSION
     US78 81 (3.0)(3.0)— 
     Intl122 126 (3.5)(6.3)2.8 
     WW200 207 (3.3)(5.0)1.7 
CARDIOVASCULAR / METABOLISM / OTHER
US1,5791,643(3.9)(3.9)— 
Intl674701(3.8)(9.9)6.1 
WW2,2532,344(3.9)(5.7)1.8 
     XARELTO
US1,158 1,086 6.6 6.6 — 
Intl  — — — 
WW1,158 1,086 6.6 6.6 — 
     INVOKANA / INVOKAMET
US183 249 (26.6)(26.6)— 
Intl127 105 20.3 12.2 8.1 
WW310 354 (12.6)(15.0)2.4 
     PROCRIT / EPREX
US121 146 (17.3)(17.3)— 
Intl133 145 (8.2)(14.1)5.9 
WW254 291 (12.8)(15.7)2.9 
     OTHER
US117 163 (27.8)(27.8)— 
Intl415 451 (8.1)(13.7)5.6 
WW532 614 (13.3)(17.4)4.1 
TOTAL PHARMACEUTICAL
US13,31512,1819.3 9.3  
Intl11,4839,70518.3 11.4 6.9 
WW$24,79821,88613.3 %10.3 %3.0 %
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US$909 620 46.7 %46.7 %— %
Intl1,08669755.7 46.4 9.3 
WW1,9951,31751.5 46.5 5.0 
ORTHOPAEDICS
US2,572 2,119 21.4 21.4 — 
Intl1,768 1,371 29.0 20.2 8.8 
WW4,340 3,489 24.4 20.9 3.5 
     HIPS
     US444 343 29.6 29.6 — 
     Intl305 220 38.3 28.6 9.7 
     WW749 563 33.0 29.2 3.8 
     KNEES
     US395 322 22.7 22.7 — 
     Intl272 196 39.2 29.5 9.7 
     WW667 517 28.9 25.2 3.7 
     TRAUMA
     US897 761 17.8 17.8 — 
     Intl545 445 22.5 14.4 8.1 
     WW1,443 1,207 19.6 16.5 3.1 
     SPINE, SPORTS & OTHER
     US836 693 20.7 20.7 — 
     Intl646 510 26.7 18.0 8.7 
     WW1,482 1,202 23.2 19.6 3.6 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (Continued)
SURGERY
US$1,933 1,334 44.9 %44.9 %— %
Intl2,961 2,317 27.8 20.4 7.4 
WW4,894 3,651 34.0 29.3 4.7 
     ADVANCED
US864 658 31.3 31.3  
Intl1,421 1,065 33.4 25.6 7.8 
WW2,286 1,723 32.6 27.8 4.8 
     GENERAL
US1,069 676 58.1 58.1  
Intl1,540 1,252 23.0 15.9 7.1 
WW2,608 1,928 35.3 30.7 4.6 
VISION
US939 687 36.6 36.6  
Intl1,389 1,075 29.2 24.6 4.6 
WW2,328 1,762 32.1 29.3 2.8 
     CONTACT LENSES / OTHER
US723 549 31.6 31.6  
Intl1,003 819 22.5 18.5 4.0 
WW1,725 1,368 26.1 23.7 2.4 
     SURGICAL
US216 138 56.3 56.3 — 
Intl386 256 50.9 44.4 6.5 
WW602 394 52.8 48.6 4.2 
TOTAL MEDICAL DEVICES
US6,353 4,760 33.5 33.5  
Intl7,204 5,460 31.9 24.5 7.4 
WW$13,557 10,220 32.7 %28.7 %4.0 %
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales